Eye Gene consortium begins first-phase clinical trial dosing of COVID-19 mRNA vaccine
Predicted impact: Medium
Phase 1 dosing start for a small biotech; meaningful milestone, size unknown.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.